StockNews.com lowered shares of CEL-SCI (NYSE:CVM – Free Report) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.
CEL-SCI Trading Down 3.5 %
CVM opened at $0.62 on Wednesday. The stock has a market cap of $39.75 million, a PE ratio of -1.07 and a beta of 0.69. The business has a 50 day moving average of $0.93 and a 200-day moving average of $1.13. CEL-SCI has a 52 week low of $0.54 and a 52 week high of $3.23. The company has a quick ratio of 0.18, a current ratio of 0.64 and a debt-to-equity ratio of 1.00.
Institutional Trading of CEL-SCI
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Tidal Investments LLC bought a new stake in CEL-SCI during the first quarter worth about $27,000. Black Diamond Financial LLC raised its holdings in CEL-SCI by 35.8% in the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after buying an additional 19,000 shares during the last quarter. Cutter & CO Brokerage Inc. lifted its stake in shares of CEL-SCI by 29.4% in the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after buying an additional 24,634 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after buying an additional 40,000 shares during the last quarter. Finally, Calton & Associates Inc. bought a new stake in shares of CEL-SCI during the third quarter valued at approximately $50,000. 12.08% of the stock is owned by hedge funds and other institutional investors.
About CEL-SCI
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
Featured Articles
- Five stocks we like better than CEL-SCI
- What Are Dividends? Buy the Best Dividend Stocks
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Compound Interest and Why It Matters When Investing
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Bank Stocks – Best Bank Stocks to Invest In
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.
